Pepcid Ac Maximum Strengthfamotidine

According to the FDA label: Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).

79,165 adverse event reports submitted to the FDA (1998–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Pepcid Ac Maximum Strength in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Pepcid Ac Maximum Strength adverse event reports by reporter sex
SexReports
Female43,107
Male27,710
Unknown67

By Age Group

View age group data as a table
Pepcid Ac Maximum Strength adverse event reports by reporter age group
Age groupReports
0-173,326
18-343,704
35-496,658
50-6414,570
65-7412,815
75+10,721

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Pepcid Ac Maximum Strength. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Pepcid Ac Maximum Strength adverse event reports by reported outcome
OutcomeReports
Other Serious33,967
Hospitalization26,687
Non-Serious25,688
Death7,778
Life-Threatening4,216
Disability1,803

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Pepcid Ac Maximum Strength. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Pepcid Ac Maximum Strength adverse event reports by year
YearReports
19981
19992
20021
2004745
2005737
2006692
2007679
2008851
2009721
20101,023
20111,564
20121,934
20131,154
20141,431
20152,550
20163,018
20173,296
20184,640
20195,537
20206,655
20216,820
20227,302
20237,391
20248,591
20259,467
2026 (partial)2,363

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Pepcid Ac Maximum Strength

In FDA adverse event reports that mention Pepcid Ac Maximum Strength, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026